Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 5,238 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Germ Cell Neoplasms Clear all

Conditions: Brain and Central Nervous System Tumors
Interventions: O6-benzylguanine, carmustine; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diffuse Intrinsic Pontine Glioma
Interventions: Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI); Drug
Lead sponsor: Sabine Mueller, MD, PhD; Other
Eligibility: 2 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pediatric Solid Tumor, Germ Cell Tumor, Retinoblastoma, Hepatoblastoma, Wilms Tumor, Rhabdoid Tumor, Carcinoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma, Clear Cell Sarcoma, Malignant Peripheral Nerve Sheath Tumors, Desmoplastic Small Round Cell Tumor, Soft Tissue Sarcoma, Neuroblastoma, Melanoma
Interventions: second generation 4-1BBζ B7H3-EGFRt-DHFR, second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG, Pembrolizumab; Biological · Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 0 Years to 26 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2040
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Glioma
Interventions: Deuterated Glucose, Magnetic Resonance Imaging (MRI), Blood Sample, MR spectroscopy (MRS); Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma
Interventions: Toca 511 vector, Toca FC; Biological · Drug
Lead sponsor: Tocagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 10
States / cities: Duarte, California • Los Angeles, California • San Diego, California + 7 more

Conditions: Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Neuroendocrine Carcinoma
Interventions: Survey Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Intraocular Melanoma, Melanoma (Skin)
Interventions: Autologous Dendritic Cells (DC), Fludarabine, Autologous Lymphocyte Infusion (ALI); Biological · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 16 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Melanoma
Interventions: WDVAX; Biological
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Neuroendocrine Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, High Grade Neuroendocrine Carcinoma, Any Site
Interventions: Pembrolizumab; Drug
Lead sponsor: Ochsner Health System; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Kenner, Louisiana • New Orleans, Louisiana

Conditions: Recurrent Melanoma, Stage IA Skin Melanoma, Stage IB Skin Melanoma, Stage IIA Skin Melanoma, Stage IIB Skin Melanoma, Stage IIC Skin Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
Interventions: Diagnostic Microscopy, Fluorescein Sodium Injection, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery; Procedure · Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Tumor, Tumors Metastatic to Brain, Adult Anaplastic Oligoastrocytoma
Interventions: bafetinib, microdialysis, pharmacological study, liquid chromatography, mass spectrometry, laboratory biomarker analysis, protein expression analysis, western blotting, immunohistochemistry staining method, therapeutic conventional surgery; Drug · Procedure · Other + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Duarte, California • South Pasadena, California

Conditions: Medulloblastoma, Neuroectodermal Tumor
Interventions: TTRNA-xALT, TTRNA-DCs; Biological
Lead sponsor: University of Florida; Other
Eligibility: Up to 30 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2025
U.S. locations: 3
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Gainesville, Florida

Conditions: Melanoma (Skin)
Interventions: oblimersen sodium, dacarbazine; Biological · Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma
Interventions: filgrastim, docetaxel; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 33
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 26 more

Conditions: Skin Cancer
Interventions: Optical Spectroscopy; Device
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 2
States / cities: Irvine, California • Orange, California

Conditions: Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology, Oncology Patients, Tumors, Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Transitional Cell Carinoma of Bladder, Colorectal Cancer
Interventions: AMG 228; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: La Jolla, California • New Haven, Connecticut • New York, New York

Conditions: Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
Interventions: Cediranib Maleate, Diffusion Tensor Imaging, Diffusion Weighted Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Fludeoxyglucose F-18, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Perfusion Magnetic Resonance Imaging, Positron Emission Tomography, Temozolomide; Drug · Procedure · Radiation + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Leukemia, Lymphoma
Interventions: Natural Killer (NK) Cell Infusion, Stem Cell Infusion; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 4 Years to 35 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Head and Neck Cancer
Interventions: filgrastim, doxorubicin hydrochloride, autologous bone marrow transplantation, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody MN-14, yttrium Y 90 monoclonal antibody MN-14; Biological · Drug · Procedure + 1 more
Lead sponsor: Garden State Cancer Center at the Center for Molecular Medicine and Immunology; Other
Eligibility: 16 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2002
U.S. locations: 2
States / cities: Belleville, New Jersey • Paterson, New Jersey

Conditions: Melanoma
Interventions: Tesetaxel; Drug
Lead sponsor: Genta Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Mesothelioma, Melanoma, Head and Neck Cancer
Interventions: CTX-471, Pembrolizumab (KEYTRUDA®); Drug
Lead sponsor: Compass Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 10
States / cities: Ocala, Florida • Port Saint Lucie, Florida • Boston, Massachusetts + 6 more

Conditions: Neuroendocrine Tumors, Von Hippel-Lindau Syndrome, Hippel-Lindau Disease
Interventions: 68Gallium DOTATATE, Radio-guided surgery; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 10 Years to 99 Years
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Mixed Oligoastrocytoma
Interventions: Bevacizumab, MLN-518 (Tandutinib), Quality-of-life assessment; Biological · Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastatic Melanoma
Interventions: High Dose Interleukin-2 (IL-2), ACT with TIL Infusion, Vemurafenib, Lymphodepletion; Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 1
States / cities: Tampa, Florida

Search by objective public record fields.

Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain

CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With Diffuse Intrinsic Pontine Glioma (DIPG) (PNOC 009)

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Assessing Brain Metabolism Using MRS With Deuterated Glucose

A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma

Assessment of What Patients and Healthcare Providers Value

Dendritic Cell Vaccination During Lymphoid Reconstruction

Dendritic Cell Activating Scaffold in Melanoma

Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma

Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery

Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases

Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor

Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301

Docetaxel in Treating Children With Recurrent Solid Tumors

A Pilot Study to Evaluate Optical Spectroscopy of Pigmented Skin Lesions

Safety Study of AMG 228 to Treat Solid Tumors

Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias

Radioimmunotherapy With or Without Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Thyroid Cancer

Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH

Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors

Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors

Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma